IMJUDO

Manufacturer:

Astrazeneca Pharmaceuticals, Lp

Name:

IMJUDO

HCPCS Code Descriptor:

Injection, tremelimumab-actl, 1 mg

Category:

J Code

HCPCS:

J9347

NDC(s):

00310-4505-25, 00310-4535-30

Primary Type:

Oncology

Generic Status:

Single-Source

Route of Administration:

Intravenous

About:

IMJUDO is a Oncology drug manufactured by Astrazeneca Pharmaceuticals, Lp and administered via the Intravenous route of administration. The J Code: J9347 is aligned to the drug IMJUDO.

IMJUDO is a cancer medication that is under the class of drugs known as Anti-CTLA-4 monoclonal antibodies. This medication binds to the CTLA-4 protein to help the immune system target cancer cells. IMJUDO is used to treat certain types of lung cancer. This drug is manufactured by Astrazeneca pharmaceuticals and is aligned to the HCPCS code J9347. Patient assistance programs can be found through Astrazeneca’s Access 360 and their AZ&Me Prescription Savings Program.